A number of research firms have changed their ratings and price targets for Amgen (NASDAQ: AMGN):

  • 9/22/2016 – Amgen had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $190.00 price target on the stock.
  • 9/20/2016 – Amgen had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $198.00 price target on the stock.
  • 9/19/2016 – Amgen had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 9/17/2016 – Amgen was given a new $206.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 9/17/2016 – Amgen had its “hold” rating reaffirmed by analysts at Leerink Swann.
  • 9/15/2016 – Amgen was given a new $193.00 price target on by analysts at Piper Jaffray Cos.. They now have a “buy” rating on the stock.
  • 9/11/2016 – Amgen had its “hold” rating reaffirmed by analysts at Leerink Swann. They now have a $193.00 price target on the stock.
  • 9/8/2016 – Amgen had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc.. They now have a $204.00 price target on the stock.
  • 8/26/2016 – Amgen had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $157.00 price target on the stock.
  • 8/26/2016 – Amgen is now covered by analysts at Gabelli. They set a “hold” rating on the stock.
  • 8/26/2016 – Amgen had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $198.00 price target on the stock, down previously from $199.00.
  • 8/26/2016 – Amgen had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $201.00 price target on the stock.
  • 8/25/2016 – Amgen was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $177.25 price target on the stock.
  • 8/23/2016 – Amgen had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $198.00 price target on the stock.
  • 8/5/2016 – Amgen had its “buy” rating reaffirmed by analysts at Argus. They now have a $195.00 price target on the stock, up previously from $185.00.
  • 8/3/2016 – Amgen had its “buy” rating reaffirmed by analysts at Jefferies Group.
  • 8/3/2016 – Amgen was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $171.34 price target on the stock.
  • 8/1/2016 – Amgen was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $166.35 price target on the stock.
  • 8/1/2016 – Amgen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Amgen’s second quarter results were impressive with the company beating on all fronts and raising its outlook again. Amgen is well-positioned for growth with several blockbuster drugs in its portfolio. Moreover, contribution from new products should be meaningful this year. Kyprolis (cancer) should gain share with both the ASPIRE and ENDEAVOR data in its label. Additionally, Amgen’s restructuring plan should make it leaner and more cost-efficient. All these factors should help Amgen achieve its raised outlook for 2016. Estimates are up signifcantly following Q2 results. Amgen’s pipeline is also progressing with quite a few regulatory and data updates scheduled for the coming quarters. Amgen is also returning value to shareholders through dividends and share buybacks. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products.”
  • 7/29/2016 – Amgen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $192.00 price target on the stock. According to Zacks, “Amgen’s Q2 results were impressive with the company topping on both earnings and revenues. Moreover, Amgen raised its 2016 outlook yet again. Amgen is well-positioned for growth with several blockbuster drugs in its portfolio. Moreover, its six growth products are performing well and their contribution should be meaningful this year. Kyprolis (cancer) should gain share with both the ASPIRE and ENDEAVOR data in its label. Additionally, Amgen’s restructuring plan should make it leaner and more cost-efficient. All these factors should help Amgen achieve its raised outlook for 2016. Amgen’s pipeline is also progressing with quite a few regulatory and data updates scheduled for the coming quarters. Amgen is also returning value to shareholders through dividends and share buybacks. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products.”
  • 7/29/2016 – Amgen had its price target raised by analysts at Citigroup Inc. from $165.00 to $175.00. They now have a “neutral” rating on the stock.
  • 7/28/2016 – Amgen had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $157.00 price target on the stock.
  • 7/28/2016 – Amgen had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $190.00 price target on the stock, up previously from $186.00.
  • 7/28/2016 – Amgen had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $201.00 price target on the stock, up previously from $186.00.
  • 7/28/2016 – Amgen had its “buy” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $206.00 price target on the stock. They wrote, “We remain focused on the two AMG 334 episodic migraine Ph3 readouts, ABP- 501 potential approval, full Ph3 FRAME results of Romosozumab and Kyprolis Clarion data in the 2H 2016.””
  • 7/28/2016 – Amgen had its price target raised by analysts at Jefferies Group from $187.00 to $198.00. They now have a “buy” rating on the stock.
  • 7/28/2016 – Amgen had its price target raised by analysts at Morgan Stanley from $198.00 to $199.00. They now have an “overweight” rating on the stock.
  • 7/28/2016 – Amgen had its “buy” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $193.00 price target on the stock.
  • 7/28/2016 – Amgen had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $185.00 price target on the stock.
  • 7/27/2016 – Amgen was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $165.78 price target on the stock.
  • 7/26/2016 – Amgen was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $162.12 price target on the stock.

Shares of Amgen Inc. (NASDAQ:AMGN) opened at 175.62 on Friday. The firm has a 50-day moving average price of $172.03 and a 200-day moving average price of $159.88. Amgen Inc. has a 12 month low of $130.09 and a 12 month high of $176.64. The stock has a market cap of $131.43 billion, a PE ratio of 17.97 and a beta of 0.87.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.58 billion. During the same period in the previous year, the business earned $2.57 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Equities analysts forecast that Amgen Inc. will post $11.36 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were paid a dividend of $1.00 per share. The ex-dividend date was Monday, August 15th. This represents a $4.00 annualized dividend and a yield of 2.28%. Amgen’s dividend payout ratio (DPR) is 40.90%.

In related news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.